Justin Stebbing

Xerion Healthcare Ltd. develops and commercializes nanoparticle treatment to cure head, and neck and lung cancer. It injects Nanoparticles into tumours and generates free radicals by splitting water rather than interacting with oxygen. The firm’s nanoparticles are based on titanium dioxide, a common, non-toxic, semiconductor material. The company was founded by Gareth Wakefield and Helen Townley in 2015 and is headquartered in Thame, the United Kingdom.